|Articles|October 19, 2016

Transplant May Still Benefit CML Patients Experiencing TKI Resistance

Author(s)Bobby Lazzara, MD

When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.

The need for allogeneic stem cell transplant in chronic myeloid leukemia (CML) patients has decreased due to tyrosine kinase inhibitor (TKI) use. But when CML patients develop resistance or intolerance to these drugs, transplant may be the only option.

This study was recently published in the journal Clinical Lymphoma, Myeloma & Leukemia and presented (abstract CML-193) at the Society of Hematologic Oncology meeting, held September 7-11, 2016, in Houston.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.

October 1st, 2026

Tabelecleucel BLA Resubmitted to FDA for EBV-Positive PTLD

Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

September 28th, 2026

Pirtobrutinib Earns Approval in China for CLL/SLL Across All Therapy Lines

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

September 24th, 2026

Anselamimab’s Kappa Subgroup Signal Could Reshape Anti-Fibril Therapy in AL Amyloidosis

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

September 23rd, 2026

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

$An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.$

September 22nd, 2026

Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS

An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.

The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.

September 22nd, 2026

Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera

The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.

Trending on CancerNetwork

Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer

What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?

SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery

Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma

CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy